Equities analysts forecast that Integra LifeSciences Holdings Corporation (NASDAQ:IART) will announce earnings of $0.47 per share for the current quarter, Zacks reports. Six analysts have provided estimates for Integra LifeSciences Holdings Corporation’s earnings. The highest EPS estimate is $0.50 and the lowest is $0.45. Integra LifeSciences Holdings Corporation also posted earnings of $0.47 per share in the same quarter last year. The company is scheduled to report its next earnings report before the market opens on Thursday, October 26th.

According to Zacks, analysts expect that Integra LifeSciences Holdings Corporation will report full-year earnings of $1.93 per share for the current fiscal year, with EPS estimates ranging from $1.92 to $1.94. For the next financial year, analysts forecast that the company will post earnings of $2.39 per share, with EPS estimates ranging from $2.35 to $2.40. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Integra LifeSciences Holdings Corporation.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The firm had revenue of $282.16 million during the quarter, compared to analysts’ expectations of $283.58 million. During the same period in the previous year, the firm posted $0.40 EPS. Integra LifeSciences Holdings Corporation’s revenue for the quarter was up 13.2% on a year-over-year basis.

Several brokerages recently issued reports on IART. Oppenheimer Holdings, Inc. set a $60.00 price target on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, October 12th. Cantor Fitzgerald began coverage on Integra LifeSciences Holdings Corporation in a report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 price target for the company. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Raymond James Financial, Inc. increased their price target on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $54.27.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. bought 2,500 shares of the stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the purchase, the director now directly owns 29,612 shares of the company’s stock, valued at $1,459,575.48. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Barbara B. Hill bought 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The shares were acquired at an average price of $49.33 per share, with a total value of $249,116.50. Following the completion of the purchase, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The disclosure for this purchase can be found here. Insiders have bought 17,550 shares of company stock valued at $864,842 over the last 90 days. Insiders own 21.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in IART. Acrospire Investment Management LLC grew its stake in shares of Integra LifeSciences Holdings Corporation by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after acquiring an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC grew its stake in shares of Integra LifeSciences Holdings Corporation by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after acquiring an additional 799 shares in the last quarter. LS Investment Advisors LLC grew its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% during the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after acquiring an additional 111 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Integra LifeSciences Holdings Corporation by 8.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after acquiring an additional 218 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Integra LifeSciences Holdings Corporation during the second quarter valued at about $174,000. Institutional investors own 84.90% of the company’s stock.

WARNING: “Integra LifeSciences Holdings Corporation (IART) Expected to Post Earnings of $0.47 Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/22/integra-lifesciences-holdings-corporation-iart-expected-to-post-earnings-of-0-47-per-share.html.

Integra LifeSciences Holdings Corporation (IART) opened at 51.53 on Friday. The firm has a market capitalization of $4.02 billion, a PE ratio of 62.84 and a beta of 0.71. The company’s 50-day moving average price is $50.62 and its 200 day moving average price is $49.69. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.